CVKD News

Following the challenges of the prior year, the 2023 IPO market started off strong with the Renaissance IPO Index climbing 16%, more than double the S&P 500's 6% gain. Seven IPOs raised $313 million, led by two issuers that raised $100+ million: property...read more

Just one small IPO began trading this week as headline deal QuantaSing Group (QSG) delayed its offering; it now plans to price in the week ahead. The pipeline continued to see more activity, with six IPOs submitting initial filings, including three planning to raise $100 million. The week’s sole deal, Cadrenal Therapeutics (CVKD) raised...read more

Cadrenal Therapeutics, a Phase 3-ready biotech developing an acquired therapy for thrombosis and AFib, raised $7 million by offering 1.4 million shares at $5, as expected. The company originally planned to offer 2 million shares before lowering the proposed offering in December. Selling shareholders concurrently registered 1.7 million shares via a separate resale prospectus, which...read more

Cadrenal Therapeutics, a Phase 3-ready biotech developing an acquired therapy for thrombosis and AFib, lowered the proposed deal size for its upcoming IPO on Tuesday. The Ponte Vedra, FL-based company now plans to raise $7 million by offering 1.4 million shares at $5. The company had previously filed to offer 2 million shares at the same price. At the revised terms, Cadrenal...read more